Table 4.
Summary of signal detection for statin-associated cancers
| Colorectal cancer |
Lung cancer |
Pancreatic cancer |
Gastric cancer |
Esophageal cancer |
Breast cancer |
Hematological malignancies |
Melanoma | Prostate cancer |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FAERS | Claims | FAERS | Claims | FAERS | Claims | FAERS | Claims | FAERS | Claims | FAERS | Claims | FAERS | Claims | FAERS | Claims | FAERS | Claims | |
| Statins | ↑ | ↑ | nd | ↑ | ↑ | ↑ | nd | nd | nd | nd | ↓ | ↓ | ↓ | nd | nd | nd | ↑ | nd |
| Simvastatin | nd | nd | ↓ | nd | ↑ | nd | ↓ | ↓ | nd | nd | ↓ | ↓ | ↓ | nd | nd | nd | nd | nd |
| Rosuvastatin# | nd | nd | nd | ↑ | ↑ | nd | nd | nd | nd | nd | ↓ | ↓ | ↓ | nd | nd | nd | ↑ | nd |
| Atorvastatin# | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | nd | nd | nd | nd | ↓ | nd | ↓ | nd | nd | nd | ↑ | nd |
| Fluvastatin | nd | nd | nd | nd | nd | nd | ↑ | nd | nd | nd | ↓ | nd | ↓ | nd | nd | nd | nd | nd |
| Pitavastatin# | nd | ↑ | ↑ | nd | nd | nd | ↑ | nd | nd | nd | ↓ | nd | nd | nd | nd | nd | ↑ | nd |
| Pravastatin | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | ↓ | nd | ↓ | ↓ | nd | nd | ↓ | nd |
| Lovastatin | nd | - | ↓ | - | nd | - | nd | - | nd | - | ↓ | - | ↓ | - | nd | - | ↑ | - |
FAERS: The US Food and Drug Administration (FDA) Adverse Event Reporting System
Claims: Claims database
↑: A positive signal was detected (This means the statin may be associated with an increased risk of cancer).
nd: A signal was not detected.
↓: A negative signal was detected (This means the statin may be associated with a decreased risk of cancer).
#: High potency statin